Skip to main content

Table 2 The baseline characteristics of subjects in the cohort from Hong Kong

From: Triglyceride-glucose index and the risk of heart failure: Evidence from two large cohorts and a mendelian randomization analysis

  

TyG index

Characteristics

Total

Q1

Q2

Q3

Q4

4.78–6.89

6.90–7.31

7.32–7.80

7.81–11.38

Subjects (n)

19,345

4,861

4,859

4,812

4,813

TyG index

7.36 ± 0.68

6.54 ± 0.27

7.10 ± 0.12

7.54 ± 0.14

8.26 ± 0.42

Age, years

60.1 ± 12.9

58.1 ± 13.9

60.6 ± 12.9

60.6 ± 12.3

61.3 ± 12.2

Male, n (%)

7738 (40.0)

1780 (36.6)

1971 (40.6)

1935 (40.2)

2052 (42.6)

Systolic BP, mmHg

139 ± 21

136 ± 21

139 ± 20

140 ± 20

142 ± 20

Diastolic BP, mmHg

76 ± 11

75 ± 12

76 ± 11

77 ± 11

77 ± 11

FBG, mmol/L

6.79 ± 3.18

5.35 ± 0.97

5.96 ± 1.41

6.72 ± 2.19

9.16 ± 4.94

TC, mg/dL

208.4 ± 42.0

197.0 ± 39.8

207.4 ± 40.9

212.4 ± 41.1

217.2 ± 43.5

LDL-c, mg/dL

124.7 ± 37.4

119.6 ± 35.5

128.3 ± 37.2

128.5 ± 37.3

122.4 ± 38.9

HDL-c, mg/dL

52.6 ± 14.6

61.0 ± 15.7

53.9 ± 14.0

49.5 ± 12.1

46.0 ± 11.7

TG, mg/dL

124.0

(88.6-179.8)

743.5

(60.2–88.6)

115.1

(98.3–132.0)

160.3

(127.5-189.5)

221.4

(159.4-292.3)

Dyslipidemia, n (%)

9099 (47.0)

1930 (39.7)

2273 (46.8)

2446 (50.8)

2450 (50.9)

Diabetes Mellitus, n (%)

6524(33.7)

559 (11.5)

1138 (23.4)

1816 (37.7)

3011 (62.6)

Hypertension, n (%)

11,809 (61.0)

2591 (53.3)

2974 (61.2)

3037 (63.1)

3207 (66.6)

Chronic kidney disease, n (%)

2930 (15.2)

543 (11.2)

730 (15.0)

744 (15.5)

913 (19.0)

Anti-hypertensive drugs, n (%)

3834 (19.8)

755 (15.5)

990 (20.4)

1011 (21.0)

1078 (22.4)

Lipid-lowering drugs, n (%)

1586 (8.2)

303 (6.2)

373 (7.7)

419 (8.7)

491 (10.2)

Diabetes drugs, n (%)

995 (5.1)

110 (2.3)

194 (4.0)

246 (5.1)

445 (9.3)

Antiplatelets, n (%)

814 (4.2)

159 (3.3)

191 (3.9)

216 (4.5)

248 (5.2)